India's pharmaceutical exports to the UK are expected to grow 8.7% to $981.16 million by FY27 under the new India-UK trade agreement. Lower tariffs on generic medicines are set to strengthen India's export competitiveness in Europe's largest market for Indian drugs. Investors may monitor how this improved market access impacts the profit margins and order volumes of major Indian pharmaceutical exporters.
Pharmaceutical exports from India to the United Kingdom are on a growth trajectory, with projections from the Pharmaceuticals Export Promotion Council of India (Pharmexcil) estimating a rise to $981.16 million by the 2026-27 fiscal year. This growth is largely expected to be driven by the India-UK Comprehensive Economic and Trade Agreement (CETA), which aims to remove tariff barriers on a wide range of pharmaceutical products.
Impact on Trade and Market Access
The UK currently stands as India’s largest pharmaceutical export destination within Europe and its third-largest globally. In the previous fiscal year, 2025-26, India exported approximately $902.96 million worth of pharmaceutical products to the UK. The new trade framework is designed to reduce the cost of entry for Indian generic drugs, potentially increasing their price competitiveness against global alternatives in the British market. Beyond lowering costs, the agreement is expected to foster closer cooperation in manufacturing standards and research, which could help Indian firms navigate regulatory requirements more efficiently.
Sector Performance and Export Composition
Indian pharmaceutical companies have already shown steady momentum in this region. During the first two months of the current fiscal year, from April to May 2026, exports to the UK grew by 4.15% year-on-year to $152.14 million. The trade balance remains heavily in India's favor, with a trade surplus of $767.49 million recorded in FY2025-26.
Drug formulations and biological products remain the primary drivers of this trade, accounting for nearly 90% of total pharmaceutical exports to the UK. Additionally, the export of Active Pharmaceutical Ingredients (APIs) and bulk drugs contributed $72.66 million last year, reflecting the UK's ongoing demand for Indian-manufactured raw materials for medicine production.
Considerations for Investors
While the reduction of trade barriers provides a favorable outlook, the actual impact on company earnings will depend on several factors. The ability of Indian firms to maintain quality compliance while scaling up exports to meet potential demand surges will be crucial. Furthermore, investors may track whether the removal of tariffs leads to increased pricing pressure from domestic UK competitors or other global suppliers. The final benefit to Indian pharmaceutical companies will depend on how effectively they can utilize this improved market access to gain volume without compromising profit margins. The next important steps to follow include the formal implementation timelines of the trade pact and any subsequent announcements regarding new manufacturing collaborations or investment plans by major Indian pharmaceutical players.